Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-046730
Filing Date
2024-11-08
Accepted
2024-11-08 17:04:56
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cpix-20240930.htm   iXBRL 10-Q 887432
2 EX-31.1 a2024q3-exhibit311.htm EX-31.1 12676
3 EX-31.2 a2024q3-exhibit312.htm EX-31.2 12669
4 EX-32.1 a2024q3-exhibit321.htm EX-32.1 6882
  Complete submission text file 0001628280-24-046730.txt   4486765

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20240930.xsd EX-101.SCH 31766
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20240930_cal.xml EX-101.CAL 53815
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20240930_def.xml EX-101.DEF 113225
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20240930_lab.xml EX-101.LAB 435825
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20240930_pre.xml EX-101.PRE 293433
60 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20240930_htm.xml XML 480283
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 241441662
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)